351 related articles for article (PubMed ID: 34319001)
1. RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway.
Xiong W; Zhang B; Yu H; Zhu L; Yi L; Jin X
Adv Sci (Weinh); 2021 Sep; 8(18):e2100881. PubMed ID: 34319001
[TBL] [Abstract][Full Text] [Related]
2. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
3. Potential tumor‑suppressive role of microRNA‑99a‑3p in sunitinib‑resistant renal cell carcinoma cells through the regulation of RRM2.
Osako Y; Yoshino H; Sakaguchi T; Sugita S; Yonemori M; Nakagawa M; Enokida H
Int J Oncol; 2019 May; 54(5):1759-1770. PubMed ID: 30816432
[TBL] [Abstract][Full Text] [Related]
4. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
Li W; Ye K; Li X; Liu X; Peng M; Chen F; Xiong W; Wang Y; Zhu L
J Exp Clin Cancer Res; 2022 Aug; 41(1):250. PubMed ID: 35974388
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway.
Han J; Hu J; Sun F; Bian H; Tang B; Fang X
Mol Cell Biochem; 2021 Feb; 476(2):689-698. PubMed ID: 33125611
[TBL] [Abstract][Full Text] [Related]
10. NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer.
Peng D; Hu Z; Wei X; Ke X; Shen Y; Zeng X
IUBMB Life; 2019 Jan; 71(1):113-124. PubMed ID: 30281919
[TBL] [Abstract][Full Text] [Related]
11. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
Rahman MA; Amin AR; Wang D; Koenig L; Nannapaneni S; Chen Z; Wang Z; Sica G; Deng X; Chen ZG; Shin DM
Clin Cancer Res; 2013 Jul; 19(13):3416-28. PubMed ID: 23719266
[TBL] [Abstract][Full Text] [Related]
12. The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment.
Cheng B; Li L; Wu Y; Luo T; Tang C; Wang Q; Zhou Q; Wu J; Lai Y; Zhu D; Du T; Huang H
Cell Biosci; 2023 Nov; 13(1):211. PubMed ID: 37968699
[TBL] [Abstract][Full Text] [Related]
13. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
15. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
17. ZDHHC2-Mediated AGK Palmitoylation Activates AKT-mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma.
Sun Y; Zhu L; Liu P; Zhang H; Guo F; Jin X
Cancer Res; 2023 Jun; 83(12):2034-2051. PubMed ID: 37078777
[TBL] [Abstract][Full Text] [Related]
18. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-κB signaling pathway.
Zhong Z; Cao Y; Yang S; Zhang S
Pharmazie; 2016 May; 71(5):280-4. PubMed ID: 27348973
[TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway.
Shan J; Wang Z; Mo Q; Long J; Fan Y; Cheng L; Zhang T; Liu X; Wang X
Pancreatology; 2022 Apr; 22(3):401-413. PubMed ID: 35300916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
